Amplia Therapeutics Ltd (ATX) - Net Assets
Based on the latest financial reports, Amplia Therapeutics Ltd (ATX) has net assets worth AU$39.47 Million AUD (≈ $27.93 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$41.44 Million ≈ $29.32 Million USD) and total liabilities (AU$1.97 Million ≈ $1.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Amplia Therapeutics Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$39.47 Million |
| % of Total Assets | 95.25% |
| Annual Growth Rate | 12.52% |
| 5-Year Change | 80.67% |
| 10-Year Change | 495.45% |
| Growth Volatility | 97.33 |
Amplia Therapeutics Ltd - Net Assets Trend (2010–2026)
This chart illustrates how Amplia Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. See ATX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Amplia Therapeutics Ltd (2010–2026)
The table below shows the annual net assets of Amplia Therapeutics Ltd from 2010 to 2026. For live valuation and market cap data, see ATX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | AU$39.47 Million ≈ $27.93 Million |
+87.74% |
| 2025-03-31 | AU$21.02 Million ≈ $14.88 Million |
+84.13% |
| 2024-03-31 | AU$11.42 Million ≈ $8.08 Million |
-27.89% |
| 2023-03-31 | AU$15.84 Million ≈ $11.20 Million |
-27.52% |
| 2022-03-31 | AU$21.85 Million ≈ $15.46 Million |
+111.29% |
| 2021-03-31 | AU$10.34 Million ≈ $7.32 Million |
+20.15% |
| 2020-03-31 | AU$8.61 Million ≈ $6.09 Million |
-0.68% |
| 2019-03-31 | AU$8.66 Million ≈ $6.13 Million |
+266.48% |
| 2018-03-31 | AU$2.36 Million ≈ $1.67 Million |
-64.33% |
| 2017-03-31 | AU$6.63 Million ≈ $4.69 Million |
+65.59% |
| 2016-03-31 | AU$4.00 Million ≈ $2.83 Million |
-17.73% |
| 2015-03-31 | AU$4.87 Million ≈ $3.44 Million |
-50.21% |
| 2014-03-31 | AU$9.77 Million ≈ $6.91 Million |
-13.02% |
| 2013-03-31 | AU$11.23 Million ≈ $7.95 Million |
+251.66% |
| 2012-03-31 | AU$3.19 Million ≈ $2.26 Million |
-47.41% |
| 2011-03-31 | AU$6.07 Million ≈ $4.30 Million |
+1.61% |
| 2010-03-31 | AU$5.98 Million ≈ $4.23 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Amplia Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6415813300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$193.43 Million | 490.04% |
| Other Comprehensive Income | AU$-1.13 Million | -2.86% |
| Total Equity | AU$39.47 Million | 100.00% |
Amplia Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Amplia Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AbL Diagnostics SA
PA:ABLD
|
$41.78 Million |
|
TWL Holdings Bhd
KLSE:7079
|
$41.78 Million |
|
CammSys Corp
KQ:050110
|
$41.79 Million |
|
Korea Electronic Certification Authority Inc
KQ:041460
|
$41.80 Million |
|
Routon Electronic Co Ltd
SHG:600355
|
$41.76 Million |
|
3I Infrastructure PLC
LSE:3IN
|
$41.75 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
$41.73 Million |
|
Samhwa Networks Co. Ltd
KQ:046390
|
$41.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amplia Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 21,024,950 to 39,472,270, a change of 18,447,320 (87.7%).
- Net loss of 7,707,152 reduced equity.
- Share repurchases of 1,858,634 reduced equity.
- New share issuances of 27,884,765 increased equity.
- Other comprehensive income decreased equity by 302,256.
- Other factors increased equity by 430,597.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-7.71 Million | -19.53% |
| Share Repurchases | AU$1.86 Million | -4.71% |
| Share Issuances | AU$27.88 Million | +70.64% |
| Other Comprehensive Income | AU$-302.26K | -0.77% |
| Other Changes | AU$430.60K | +1.09% |
| Total Change | AU$- | 87.74% |
Book Value vs Market Value Analysis
This analysis compares Amplia Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.37x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.41x to 1.37x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-03-31 | AU$0.28 | AU$0.12 | x |
| 2011-03-31 | AU$0.29 | AU$0.12 | x |
| 2012-03-31 | AU$0.15 | AU$0.12 | x |
| 2013-03-31 | AU$0.65 | AU$0.12 | x |
| 2014-03-31 | AU$0.75 | AU$0.12 | x |
| 2015-03-31 | AU$0.26 | AU$0.12 | x |
| 2016-03-31 | AU$0.19 | AU$0.12 | x |
| 2017-03-31 | AU$0.28 | AU$0.12 | x |
| 2018-03-31 | AU$0.09 | AU$0.12 | x |
| 2019-03-31 | AU$0.20 | AU$0.12 | x |
| 2020-03-31 | AU$0.16 | AU$0.12 | x |
| 2021-03-31 | AU$0.11 | AU$0.12 | x |
| 2022-03-31 | AU$0.15 | AU$0.12 | x |
| 2023-03-31 | AU$0.08 | AU$0.12 | x |
| 2024-03-31 | AU$0.06 | AU$0.12 | x |
| 2025-03-31 | AU$0.07 | AU$0.12 | x |
| 2026-03-31 | AU$0.08 | AU$0.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amplia Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-19.53%) is above the historical average (-60.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -67.99% | 0.00% | 0.00x | 1.37x | AU$-4.66 Million |
| 2011 | -40.21% | 0.00% | 0.00x | 1.29x | AU$-3.05 Million |
| 2012 | -101.84% | 0.00% | 0.00x | 1.80x | AU$-3.57 Million |
| 2013 | -30.16% | 0.00% | 0.00x | 1.02x | AU$-4.51 Million |
| 2014 | -46.00% | 0.00% | 0.00x | 1.04x | AU$-5.47 Million |
| 2015 | -107.62% | -17278.70% | 0.01x | 1.09x | AU$-5.72 Million |
| 2016 | -123.48% | -218.40% | 0.45x | 1.26x | AU$-5.34 Million |
| 2017 | -106.75% | -393.54% | 0.24x | 1.14x | AU$-7.74 Million |
| 2018 | -181.77% | -740.59% | 0.22x | 1.12x | AU$-4.53 Million |
| 2019 | -21.58% | -3704.79% | 0.01x | 1.06x | AU$-2.74 Million |
| 2020 | -25.79% | -6484.57% | 0.00x | 1.06x | AU$-3.08 Million |
| 2021 | -22.06% | -148.75% | 0.14x | 1.05x | AU$-3.32 Million |
| 2022 | -16.68% | -183.74% | 0.08x | 1.12x | AU$-5.83 Million |
| 2023 | -39.42% | -524.80% | 0.06x | 1.18x | AU$-7.83 Million |
| 2024 | -39.44% | -101.14% | 0.30x | 1.30x | AU$-5.65 Million |
| 2025 | -31.26% | -173.69% | 0.16x | 1.09x | AU$-8.67 Million |
| 2026 | -19.53% | 0.00% | 0.00x | 1.05x | AU$-11.65 Million |
Industry Comparison
This section compares Amplia Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $10,245,469
- Average return on equity (ROE) among peers: -152.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amplia Therapeutics Ltd (ATX) | AU$39.47 Million | -67.99% | 0.05x | $41.77 Million |
| Adalta Ltd (1AD) | $172.82K | -722.64% | 1.66x | $5.41 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $7.52 Million | -54.40% | 0.16x | $14.31 Million |
| ACRUX Ltd (ACR) | $12.85 Million | -73.71% | 0.44x | $4.36 Million |
| Actinogen Medical Ltd (ACW) | $12.13 Million | -29.97% | 0.07x | $78.71 Million |
| Argenica Therapeutics Ltd (AGN) | $8.31 Million | -49.24% | 0.09x | $10.00 Million |
| Arovella Therapeutics Ltd (ALA) | $6.69 Million | -24.93% | 0.60x | $60.73 Million |
| Anatara Lifesciences Ltd (ANR) | $-16.00K | 0.00% | 0.00x | $1.92 Million |
| Alterity Therapeutics Ltd (ATH) | $39.11 Million | -15.05% | 0.07x | $108.75 Million |
| Avecho Biotechnology Ltd (AVE) | $5.45 Million | -398.12% | 0.01x | $40.65 Million |
About Amplia Therapeutics Ltd
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develo… Read more